✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Masitinib is an investigational drug.
There have been 36 clinical trials for Masitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 25th 2008.
The most common disease conditions in clinical trials are Sclerosis, Mastocytosis, and Gastrointestinal Stromal Tumors. The leading clinical trial sponsors are AB Science and [disabled in preview].
Recent Clinical Trials for Masitinib
|Masitinib for the Treatment of Severe Mast Cell Activation Syndrome||AB Science||Phase 2|
|Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis||AB Science||Phase 3|
|Masitinib in Patients With Symptomatic Mild to Moderate COVID-19||AB Science||Phase 2|